Miltenyi Biomedicine GmbH
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Private
- Established
- 2019-01-01
- Employees
- 51
- Market Cap
- -
Clinical Trials
40
Active:18
Completed:4
Trial Phases
4 Phases
Early Phase 1:1
Phase 1:23
Phase 2:5
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (38 trials with phase data)• Click on a phase to view related trials
Phase 1
23 (60.5%)phase_1_2
5 (13.2%)Phase 2
5 (13.2%)Not Applicable
4 (10.5%)Early Phase 1
1 (2.6%)MB-CART2019.1 in Refractory Multiple Sclerosis
Not Applicable
Not yet recruiting
- Conditions
- Multiple SclerosisCAR T Cell Therapy
- Interventions
- First Posted Date
- 2025-09-17
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 26
- Registration Number
- NCT07178431
- Locations
- 🇩🇪
Charité Universitätsmedizin Berlin, Berlin, Germany
US Zamto-cel Autoimmune Diseases
Phase 1
Not yet recruiting
- Conditions
- Lupus NephritisSystemic Lupus ErythematosusSystemic Sclerosis (SSc)Diffuse Cutaneous Systemic Sclerosis
- Interventions
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 48
- Registration Number
- NCT06708845
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
Not Applicable
Recruiting
- Conditions
- Childhood Non-Hodgkin LymphomaChronic Lymphatic LeukemiaMelanoma Stage IIIMelanoma Stage IVAcute Lymphatic LeukemiaB-cell Non Hodgkin LymphomaPediatric ALL
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 40
- Registration Number
- NCT06508775
- Locations
- 🇩🇪
Universitätsklinikum Köln, Cologne, Germany
🇩🇪Universitätsmedizin Göttingen, Göttingen, Germany
🇩🇪Universitätsklinikum Münster, Münster, Germany
Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With Relapsed or Refractory B-Cell Neoplasms
Phase 2
Recruiting
- Conditions
- B-Cell Neoplasm
- Interventions
- Drug: zamtocabtagene autoleucel (MB-CART2019.1)
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-09-26
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 31
- Registration Number
- NCT06508931
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
MB-dNPM1-TCR.1 in Relapsed/refractory AML
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Miltenyi Biomedicine GmbH
- Target Recruit Count
- 29
- Registration Number
- NCT06424340
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found